Chemical mapping as a predictor of vein of Marshall ethanol ablative effects

PURPOSE

The aim of this study was to test regional pharmacological effects of an antiarrhythmic agents to predict ablative effects.

BACKGROUND

The vein of Marshall (VOM) providing vascular access to myocardial tissue has been used for ablative purposes using ethanol.

METHODS

A total of 35 patients (male 21, 63.2 ± 7.8 years old) were included. A balloon-tipped infusion catheter was inserted into the VOM. Endocardial ultrahigh-resolution mapping was performed along the VOM region to record the change in atrial electrograms (AEs) after VOM injection of cibenzoline of 3.5 mg during sustained atrial fibrillation (AF). Subsequently, ethanol was infused into the VOM and ablative region was mapped.

RESULTS

In 17 patients (49 %), cibenzoline reduced AEs amplitude by >50%, all of which had also complete elimination of AEs following ethanol (Group A). In 18 patients (Group B), cibenzoline failed to eliminate AEs; yet, in 13 of 18 AEs were eliminated by ethanol. In the remaining five patients, ethanol did not eliminate AE.

CONCLUSIONS

Cibenzoline into the VOM could reliably predicts the results of subsequent ethanol infusion into the VOM using ultrahigh-resolution mapping system, which leads to avoid unnecessary permanent lesion creation by ethanol infusion.

Ethanol for the treatment of cardiac arrhythmias

INTRODUCTION

Ethanol infusion was an early mode of ablative treatment for cardiac arrhythmias. Its initial descriptions involved coronary intra-arterial delivery, targeting arrhythmogenic substrates in drug-refractory ventricular tachycardia or the atrioventricular node. Largely superseded by radiofrequency ablation (RFA) and other contact-based technologies as a routine ablation strategy, intracoronary arterial ethanol infusion remains as an alternative option in the treatment of ventricular tachycardia when conventional ablation fails. Arrhythmic foci that are deep-seated in the myocardium may not be amenable to catheter ablation from either the endocardium or the epicardium by RFA, but they can be targeted by an ethanol infusion.

RECENT FINDINGS

Recently, we have explored ethanol injection through cardiac venous systems, in order to avoid the risks of complications and limitations of coronary arterial instrumentation. Vein of Marshall ethanol infusion is being studied as an adjunctive procedure in ablation of atrial fibrillation, and coronary venous ethanol infusion for ventricular tachycardia.

CONCLUSION

Ethanol ablation remains useful as a bail-out technique for refractory cases to RFA, or as an adjunctive therapy that may improve the efficacy of catheter ablation procedures.

[Transcatheter subendocardial infusion: a novel technique for ablation of atrial arrhythmias]

Ablation of typical atrial flutter using radiofrequency energy is limitted by difficulties in creating a continuous line of block across the istmus between the tricuspid anulus and the inferior vena cava. Recent studies from our laboratory have shown that a novel infusion ablation technique can create large endocardial lesions in a safe and predictable fashion. The purpose of our study was to assess the feasibility of transcatheter subendocardial infusion of a mixture of 95% enthanol, iodinated contrast and glycerin to create atrial lesions resulting in complete ablation of the critical isthmus mediating typical atrial flutter.

METHODS

Seven closed-chest dogs (weight 24+/-1 kg) were studied during general anesthesia with isoflurane. Two transcatheter subendocardial infusions of 0.5 cc of ethanol, contrast medium and glycerin were made over an injection time of 5 s into the posterior right atrial isthmus in each dog. Staining of the target site was monitored on fluoroscopy. Sinus rate, AH interval and AV block cycle length were determined before and after infusion ablation. Arterial blood pressure and right atrial pressure were continuously recorded. Six infusion ablations were also performed in the lateral wall of the right atrium. Lesion dimensions were measured pathologically, thereafter.

RESULTS

A total of 14 infusions was made in the isthmus of the right atrium. The mean lesion volume was 0.21+/-0.18 cc. The lesions were 6+/-3 mm in width, the length was 12+/-5 mm and the average deepness was 6+/-4 mm. An ablation of the entire isthmus was, achieved in five dogs. Disturbances in AV conduction were not observed after ablation in any dog. The isthmus lesions were not proarrhythmic during programmed stimulation. 4/6 infusion ablations in the lateral atrial wall caused a penetration of contrast media of the pericardial sac. Hemodynamic deterioration was not seen after any ablation attempt.

CONCLUSIONS

Direct subendocardial insusions can be used to create large ablation lesions in the posterior right atrium. The lesion size is predictable and can be directly visualized on fluoroscopy. Infusion ablations into the right atrial isthmus do not cause damage to the AV node or to the right coronary artery. Transcatheter infusions in the posterior right atrium seem to be promising for ablation of the entire isthmus mediating typical atrial flutter. Additional studies of this technique in an arrhythmia model seem warranted.

Transcatheter subendocardial infusion. A novel technique for mapping and ablation of ventricular myocardium

BACKGROUND

Catheter ablation with radiofrequency energy is feasible in a limited subset of patients with ventricular tachycardia. The purpose of this study was to evaluate a technique for mapping and ablation of ventricular myocardium with the use of transcatheter subendocardial infusion.

METHODS AND RESULTS

A needle-tipped deflectable electrode catheter was used to deliver reagents to endocardial target sites. This was equipped with two central lumens to allow sequential administration of mapping and ablation injectants with minimal admixture. The mapping injectant consisted of a mixture of lidocaine, iohexal, and glycerin; the ablation injectant contained ethanol, iohexal, and glycerin. Infusion of the mapping injectant (1 cm3 over 3 or 5 seconds, n = 14) produced a stain on fluoroscopy and increased local capture threshold by 61%. No lesions resulted from mapping infusions. Infusion of the ethanol-containing injectant (n = 48) produced discrete lesions, with a mean volume ranging from 0.6 to 1.5 cm3. There was a direct relationship between infusion volume, infusion duration, and resultant lesion volume. Fibrosis in a region of healed myocardial infarction did not impair diffusion of the injectant or affect lesion dimensions. Microscopic analysis of chronic lesions showed a sharply demarcated border zone between fibrotic and normal myocardium.

CONCLUSIONS

Transcatheter subendocardial infusion can be used to reversibly impair local excitability and mark an injection site fluoroscopically. Subendocardial injection of ethanol can predictably ablate a large volume of ventricular myocardium. Additional study of this system in an arrhythmia model will help to define its potential for mapping and ablation of hypotensive ventricular tachycardia.

Ablative therapy for ventricular arrhythmias

Radiofrequency catheter ablation techniques have enjoyed successful applications in patients with a wide variety of supraventricular tachycardias, especially the Wolff-Parkinson-White syndrome and atrioventricular nodal reentry. More recent reports have shown successful applications in patients with atrial tachycardias and atrial flutter. In addition to these, there are now reports of success during attempts to use radiofrequency techniques to eliminate ventricular tachycardia (VT), both in patients without structural heart disease (idiopathic VT) and patients with structural heart disease (primarily coronary artery disease). Techniques to map sites for ablation in patients with idiopathic VT usually include identifying early endocardial activation and using pace mapping. Success rates for ablation of idiopathic VT have been very high (over 90%) in patients with VT arising from the right ventricular outflow tract. Success rates have not been quite as high when VTs arising from sites other than the right ventricular outflow tract are targeted in the patient with idiopathic VT. In patients with VT caused by coronary artery disease, early endocardial activation and pace mapping can be unreliable. In these patients, searching for mid-diastolic potentials or showing concealed entrainment have proved more reliable. When these latter techniques are applied, success rates in eliminating a single focus of VT in a patient with coronary artery disease has been reported to be as high as 60% to 80%. Future therapies will include new energy sources, new (larger and/or cooled) electrodes, and multipoint catheter mapping, possibly using body surface mapping techniques.